The crosstalk between MET amplification and the Wnt/β‐catenin signaling pathway was further investigated through gene expression and survival analysis in a cohort of 66 EGFR mutated NSCLC patients without any non‐tumor related diseases, which were carefully selected from the GEO database. This evidence concerns the gene EGFR and non-small cell lung carcinoma.